News &amp; Updates

Treating gout patients with urate-lowering therapy (ULT) to meet a serum urate level below 6 mg/dL within 12 months results in a reduced risk of major adverse cardiovascular events, as shown in a new user cohort study.

Treat-to-target ULT approach reduces cardiac risk in gout patients

Native vessel vs SVG PCI: Which procedure is more effective?

Percutaneous coronary intervention (PCI) of the saphenous vein graft (SVG) results in improvements in 1-year clinical outcomes relative to native vessel PCI, reports a study.

Native vessel vs SVG PCI: Which procedure is more effective?

PHP a promising alternative to endoscopic clip for post-EST bleeding

In patients with postendoscopic sphincterotomy (post-EST) bleeding, polysaccharide hemostatic powder (PHP) demonstrates noninferiority to endoscopic clip in the management of post-EST bleeding and is easier to use, reports a study.

PHP a promising alternative to endoscopic clip for post-EST bleeding

Acute gastroenteritis ups DGBI risk in children

Disorders of gut-brain interaction (DGBIs) tend to develop more in children in acute gastroenteritis (AGE), according to a study. Moreover, an association is seen between AGE symptom severity and postinfectious (PI) DGBI.

Acute gastroenteritis ups DGBI risk in children

COMMIT: Triplet regimen extends PFS in select CRC patients

In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).

COMMIT: Triplet regimen extends PFS in select CRC patients

04 Feb 2026

Obesity linked to poorer PFS in pembrolizumab-treated endometrial cancer

Among patients with endometrial cancer receiving treatment with pembrolizumab, those with obesity appear to have worse progression-free survival (PFS), according to a retrospective study.

Obesity linked to poorer PFS in pembrolizumab-treated endometrial cancer

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (¹⁷⁷Lu)-Dotatate significantly improved progression-free survival (PFS) among Asian patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), according to the LUMINET-1 study presented at ESMO Asia 2025.

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

Among patients of very advanced age, those with nocturnal hypertension are at increased risk of adverse cardiovascular outcomes, as reported in a study.

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

03 Feb 2026 by

In the treatment of uncomplicated urogenital gonorrhoea, a single dose of the novel oral antibiotic zoliflodacin shows similar efficacy and safety profile as the ceftriaxone plus azithromycin combination, as shown in a multinational phase III study.

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients

Several factors tend to increase the risk of venous thromboembolism (VTE) in patients with gynaecologic malignant tumours after surgery, reveals a study.

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients